Several other brokerages also recently issued reports on HSKA. Zacks Investment Research downgraded shares of Heska from a hold rating to a strong sell rating in a research note on Tuesday, March 8th. StockNews.com began coverage on shares of Heska in a research note on Thursday, March 31st. They set a hold rating for the company. JPMorgan Chase & Co. cut their price objective on shares of Heska from $300.00 to $250.00 and set an overweight rating on the stock in a report on Wednesday, February 23rd. TheStreet lowered shares of Heska from a c- rating to a d+ rating in a report on Friday, February 11th. Finally, Morgan Stanley cut their price target on shares of Heska from $190.00 to $161.00 and set an equal weight rating on the stock in a report on Tuesday, March 1st. One investment analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of Hold and a consensus target price of $219.83.
HSKA opened at $100.62 on Thursday. The firm has a market cap of $1.09 billion, a P/E ratio of -79.23 and a beta of 1.64. Heska has a 12 month low of $82.92 and a 12 month high of $275.94. The company has a current ratio of 6.73, a quick ratio of 5.37 and a debt-to-equity ratio of 0.23. The stock has a 50-day moving average of $125.32 and a 200 day moving average of $145.12.
Several institutional investors have recently bought and sold shares of HSKA. Northwestern Mutual Wealth Management Co. increased its position in shares of Heska by 132.0% in the first quarter. Northwestern Mutual Wealth Management Co. now owns 232 shares of the medical research company’s stock valued at $32,000 after buying an additional 132 shares in the last quarter. First Horizon Advisors Inc. increased its position in shares of Heska by 1,944.4% in the fourth quarter. First Horizon Advisors Inc. now owns 184 shares of the medical research company’s stock valued at $33,000 after buying an additional 175 shares in the last quarter. Altshuler Shaham Ltd purchased a new stake in shares of Heska in the third quarter valued at approximately $49,000. Pinebridge Investments L.P. acquired a new stake in shares of Heska in the fourth quarter worth approximately $55,000. Finally, Point72 Hong Kong Ltd acquired a new stake in shares of Heska in the first quarter worth approximately $57,000. Institutional investors and hedge funds own 95.94% of the company’s stock.
About Heska (Get Rating)
Heska Corporation sells veterinary and animal health diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Mexico, Australia, France, Germany, Italy, Malaysia, Spain, and Switzerland. The company offers Element DC, Element DCX, Element DC5x veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element RC, Element RCX, and Element RC3X chemistry systems for blood chemistry and electrolyte analysis; Element HT5 and scil Vet abc Plus veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; and Element COAG and Element AIM veterinary analyzers.
- Get a free copy of the StockNews.com research report on Heska (HSKA)
- MarketBeat: Week in Review 5/16 – 5/20
- 3 Retailers That Defied First Quarter Headwinds
- Will John Deere’s Earnings Help to Calm the Markets?
- Rapid7: Could Be Profitable in FY 2022 Despite Bear Market
- Lowe’s Companies Has Not Bottomed
Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.